Screening for lung cancer: Does MRI have a role?

Biederer, J.; Ohno, Yoshiharu; Hatabu, Hiroto; Schiebler, Mark L.; Beek, Edwin Jacques Rudolph van; Vogel‐Claussen, Jens; Kauczor, Hans‐Ulrich

doi:10.1016/j.ejrad.2016.09.016

Cited by 67 publications

(47 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the Lung CT Screening Reporting and Data System (Lung-RADS), individuals with nodules ≥ 6 mm should undergo six-month follow-up, and nodules ≥ 8 mm require three-month follow-up or further evaluation (12). Previous studies reported a sensitivity of 60–90% for MRI for the detection of nodules with a size of 4–8 mm, reaching 100% for nodules ≥ 8 mm (4–8).…”

Section: Introductionmentioning

confidence: 99%

Lung cancer screening with MRI: characterization of nodules with different non-enhanced MRI sequences

et al. 2018

View full text Add to dashboard Cite

Background There is increased interest in pulmonary magnetic resonance imaging (MRI) as a radiation-free alternative to computed tomography (CT) for lung cancer screening. Purpose To analyze MRI characteristics of pulmonary nodules with different non-enhanced sequences. Material and Methods Eighty-two participants of a lung cancer screening were included. MRI datasets of 32 individuals with 46 different nodules ≥ 6 mm were prospectively evaluated together with 50 controls by two readers. Acquired sequences were T2- short tau inversion recovery (STIR), T2, balanced steady-state free precession (bSSFP), 3D-T1, and diffusion-weighted imaging (DWI). Each sequence was randomly and separately viewed blinded to low-dose CT (LDCT). Size, shape, and contrast of nodules were evaluated on each sequence and then correlated with LDCT and histopathology. Results All eight carcinomas were detected by T2-STIR, T2, and bSSFP, and 7/8 by 3D-T1. Contrast was significantly higher for malignant nodules on all sequences. The highest contrast ratio between malignant and benign nodules was provided by T2-STIR. Of eight carcinomas, seven showed restricted diffusion. Size measurement correlated significantly between MRI and LDCT. Sensitivity/specificity for nodules ≥ 6 mm was 85-89%/92-94% for T2-STIR, 80-87%/93-96% for T2, 65-70%/96-98% for bSSFP, and 63-67%/96-100% for 3D-T1. Seven of eight subsolid nodules were visible on T2-sequences with significantly lower lesion contrast compared to solid nodules. Two of eight subsolid nodules were detected by bSFFP, none by 3D-T1. All three calcified nodules were detected by 3D-T1, one by bSSFP, and none by T2-sequences. Conclusion Malignant as well as calcified and subsolid nodules seem to have distinctive characteristics on different MRI sequences. T2-imaging was most suitable for the detection of nodules ≥ 6 mm.

show abstract

Section: Introductionmentioning

confidence: 99%

Lung cancer screening with MRI: characterization of nodules with different non-enhanced MRI sequences

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In a recent review, Biederer et al explored MR data, including UTE and bSSFP, outlining the diagnostic challenges of using MRI for detection, primary or otherwise, of small malignant lesions [20]. The authors discussed potential scenarios in which MRI could play a role moving forward, from no contribution to an adjunct or replacement to CT, depending on further validation of diagnostic quality and cost.…”

Section: Advances In Mri Technologymentioning

confidence: 99%

“…The authors discussed potential scenarios in which MRI could play a role moving forward, from no contribution to an adjunct or replacement to CT, depending on further validation of diagnostic quality and cost. They ultimately concluded that while technical feasibility has been achieved, validation of better patient outcomes with MRI are still lacking [20]. Despite these limitations, for lesions near the chest wall, vertebral body, or near the mediastinum, MRI can provide more accurate staging due to its improved soft tissue contrast compared to CT and ability to identify local invasion of adjacent structures, including the mediastinum, ribs, nerve roots, pleura, which provide crucial information for staging [21] (Fig.…”

Section: Advances In Mri Technologymentioning

confidence: 99%

A review of the role of MRI in diagnosis and treatment of early stage lung cancer

Sim

Kaza

Singer

et al. 2020

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Despite magnetic resonance imaging (MRI) being a mainstay in the oncologic care for many disease sites, it has not routinely been used in early lung cancer diagnosis, staging, and treatment. While MRI provides improved soft tissue contrast compared to computed tomography (CT), an advantage in multiple organs, the physical properties of the lungs and mediastinum create unique challenges for lung MRI. Although multi-detector CT remains the gold standard for lung imaging, advances in MRI technology have led to its increased clinical relevance in evaluating early stage lung cancer. Even though positron emission tomography is used more frequently in this context, functional MR imaging, including diffusionweighted MRI and dynamic contrast-enhanced MRI, are emerging as useful modalities for both diagnosis and evaluation of treatment response for lung cancer. In parallel with these advances, the development of combined MRI and linear accelerator devices (MR-linacs), has spurred the integration of MRI into radiation treatment delivery in the form of MR-guided radiotherapy (MRgRT). Despite challenges for MRgRT in early stage lung cancer radiotherapy, early data utilizing MR-linacs shows potential for the treatment of early lung cancer. In both diagnosis and treatment, MRI is a promising modality for imaging early lung cancer.

show abstract

“…Early detection has been associated with a 20% reduction in lung cancer mortality; yet, annual use of LDCT increases an individual patient's risk of radiation induced cancer by 0.5%-5.5% (10). Thus, there has been ongoing development for the use of MRI in early detection lung cancer screening as an alternative to LDCT (11,12). Overall, there is minimal immediate concern for MR utilization in the high risk lung cancer patient cohort.…”

Section: Screening and Diagnosismentioning

confidence: 99%

Neuromodulation and the Epidemiology of Magnetic Resonance Utilization for Lung, Breast, Colon, and Prostate Cancer

Jotwani

Mehta

Baig

et al. 2020

Neuromodulation: Technology at the Neural Interface

View full text Add to dashboard Cite

Screening for lung cancer: Does MRI have a role?

Cited by 67 publications

References 42 publications

Lung cancer screening with MRI: characterization of nodules with different non-enhanced MRI sequences

Lung cancer screening with MRI: characterization of nodules with different non-enhanced MRI sequences

A review of the role of MRI in diagnosis and treatment of early stage lung cancer

Neuromodulation and the Epidemiology of Magnetic Resonance Utilization for Lung, Breast, Colon, and Prostate Cancer

Contact Info

Product

Resources

About